ADC Total Operating Expenses from 2010 to 2025
| ADCT Stock | USD 1.49 0.03 1.97% |
Total Operating Expenses | First Reported 2018-03-31 | Previous Quarter 44.4 M | Current Value 53.2 M | Quarterly Volatility 19.5 M |
Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 2.7 M or Interest Expense of 55.9 M, as well as many indicators such as Price To Sales Ratio of 2.65, Dividend Yield of 0.0 or Days Sales Outstanding of 210. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.
ADC | Total Operating Expenses |
Latest ADC Therapeutics' Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of ADC Therapeutics SA over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. ADC Therapeutics' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
ADC Total Operating Expenses Regression Statistics
| Arithmetic Mean | 160,177,615 | |
| Geometric Mean | 141,766,480 | |
| Coefficient Of Variation | 53.21 | |
| Mean Deviation | 75,646,518 | |
| Median | 121,739,000 | |
| Standard Deviation | 85,230,865 | |
| Sample Variance | 7264.3T | |
| Range | 235.5M | |
| R-Value | 0.82 | |
| Mean Square Error | 2515T | |
| R-Squared | 0.68 | |
| Significance | 0.000091 | |
| Slope | 14,728,354 | |
| Total Sum of Squares | 108964.5T |
ADC Total Operating Expenses History
About ADC Therapeutics Financial Statements
ADC Therapeutics shareholders use historical fundamental indicators, such as Total Operating Expenses, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 268 M | 222.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.